Physician profile
Raja C Pullatt
NPI 1477746634
$5,352.69
in general payments reported to CMS, 2019-2025
30 companies · $968 in 2025
The $968 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $475 · 2021: $343 · 2022: $487 · 2023: $1,091 · 2024: $1,149 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,167 · Education: $39.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.46 |
| Education | $39.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,099.35 | 2019-2024 | Da Vinci Surgical System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $499.51 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $367.03 | 2022-2025 | Verquvo, Capvaxive |
| Amgen INC. | $363.14 | 2019-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $292.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $285.93 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $282.99 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $266.97 | 2023-2025 | Watchman Flx, General - Therapies |
| Medtronic, INC. | $264.90 | 2024 | Signia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.94 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $187.81 | 2022-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $184.20 | 2019-2025 | |
| Pfizer INC. | $171.12 | 2019-2025 | |
| Edwards Lifesciences Corporation | $154.76 | 2022-2025 | Sapien 3 Ultra Resilia |
| W. L. Gore & Associates, INC. | $134.38 | 2023 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $126.00 | 2019-2025 | Camzyos |
| Medtronic Vascular, INC. | $122.67 | 2020 | |
| Abbott Laboratories | $54.42 | 2019-2025 | Gallant, Aveir |
| Bayer Healthcare Pharmaceuticals INC. | $52.10 | 2025 | |
| Heartflow, INC. | $45.94 | 2024-2025 | |
| Bridgebio Pharma, INC. | $36.14 | 2025 | Attruby |
| Abiomed | $35.35 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $31.87 | 2024 | Arcalyst |
| Cleerly, INC. | $25.62 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Kowa Pharmaceuticals America, INC. | $24.47 | 2019-2020 | |
| Esperion Therapeutics, INC. | $15.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.41 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.82 | 2019 | |
| Allergan, INC. | $11.67 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raja Pullatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.